Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China.

Weijia WuShuyi DingZhang MingmingZhou YupingXueshan SunZixuan ZhaoYi YangYongxian HuHengjin Dong

Published in: Journal of medical economics (2023)

Base on the willingness-to-pay of 3 times China's per capita GDP in 2021, Cilta-cel was considered to be a more cost-effective option compared to salvage chemotherapy for RRMM in China, while Ide-cel was not.

Keyphrases

cell therapy
multiple myeloma
acute lymphoblastic leukemia
squamous cell carcinoma
mesenchymal stem cells
radiation therapy
acute myeloid leukemia
health insurance